Pharmaceutical Executive's 2021 Emerging Pharma Leaders
Pharm Exec profiles 13 diverse leaders vital to the future of the biopharma industry.
Click on the links below to read the profiles of Pharm Exec's 2021 Emerging Pharma Leaders.
Karen Akinsanya, Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D, Schrödinger
Sally Allain, Head of Johnson & Johnson Innovation, LLC – JLABS @ Washington, DC
Daniel Getts, CEO, Myeloid Therapeutics
Simba Gill, PhD, CEO, Evelo Biosciences
Michael Henderson, MD, Chief Business Officer, BridgeBio Pharma
Donna Hunt Hodge, Director, New Product Development, Inherited Retinal Diseases, Johnson & Johnson
John Hoekman, PhD, Co-Founder & Chief Scientific Officer, Impel NeuroPharma
Lukasz Jarzyna, Head of Global Value, Access, and Pricing, Alexion Pharmaceuticals
William “BJ” Jones, Chief Commercial Officer, Migraine & Common Disease, Biohaven Pharmaceuticals
Kirsten Kester, Vice President, Business Development, Obsidian Therapeutics
Carsten Linnemann, PhD, CEO, Neogene Therapeutics
Carla Pearson, Vice President and Global Commercial Lead for Cabotegravir, ViiV Healthcare
Teisha Robinson, Director of Strategic Accounts-Emerging Accounts, Johnson & Johnson Health Care Systems Inc.
*From a pool of over 100 nominations, these final selections were judged in a blinded process by three Editorial Advisory Board members and a former EPL.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
